NantKwest, Inc. (NK): Price and Financial Metrics
NK Price/Volume Stats
| Current price | $32.49 | 52-week high | $45.42 |
| Prev. close | $28.28 | 52-week low | $2.52 |
| Day low | $29.74 | Volume | 1,109,000 |
| Day high | $33.15 | Avg. volume | 1,568,129 |
| 50-day MA | $22.98 | Dividend yield | N/A |
| 200-day MA | $12.74 | Market Cap | 3.55B |
NK Stock Price Chart Interactive Chart >
NantKwest, Inc. (NK) Company Bio
NantKwest is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. The company was founded in 2002 and is based in Cardiff-by-the-Sea, California.
Latest NK News From Around the Web
Below are the latest news stories about NantKwest Inc that investors may wish to consider to help them evaluate NK as an investment opportunity.
ImmunityBio and NantKwest Complete MergerImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditions, including approval of the merger by a majority of unaffiliated shareholders of NantKwest at its Special Meeting held on March 8, 2021. The combined company will operate under the name ImmunityBio, Inc. ("ImmunityBio") and its shares of common stock will commence trading on NASDAQ on March 10, 2021 under the new ticker "IBRX." |
NantKwest's Charts Are Extended When Compared to the Popular Moving AveragesDuring Friday's "Lightning Round" segment of Mad Money, one caller quizzed Jim Cramer about NantKwest . In this daily bar chart of NK, below, we can see that prices made a base down in the $5 area before rallying in December and soaring into February. NK is trading above the rising 50-day moving average line and is extended (overbought) when compared to the rising 200-day line which intersects down at only $12. |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - CTB, PBCT, HMSY, NK, SPWHHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Merger InvestigationWILMINGTON, Del., Feb. 20, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating: NantKwest, Inc. (NASDAQ GS: NK) regarding possible breaches of fiduciary duties and other violations of law related to NantKwest’s agreement to merge with ImmunityBio, Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-nantkwest-inc. Cardtronics plc (NASDAQ GS: CATM) regarding possible breaches of fiduciary duties and other violations of law related to Cardtronics’ agreement to be acquired by affiliates of Apollo Global Management, Inc. and Hudson Executive Capital LP. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-cardtronics-plc. Landcadia Holdings III, Inc. (NASDAQ GS: LCYAU) regardin... |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates AEGN, FFG, NK, GWPH; Shareholders Are Encouraged to Contact the FirmNEW YORK, NY / ACCESSWIRE / February 20, 2021 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:Aegion Corporation (NASDAQ:AEGN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to affiliates of New Mountain Capital, L. If you are an Aegion shareholder, click here to learn more about your rights and options. |
NK Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | 2,700.86% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 251.72% |
| 2019 | 226.72% |
Continue Researching NK
Want to do more research on NantKwest Inc's stock and its price? Try the links below:NantKwest Inc (NK) Stock Price | Nasdaq
NantKwest Inc (NK) Stock Quote, History and News - Yahoo Finance
NantKwest Inc (NK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...